- Conditions: Unipolar Depression; Bipolar Depression
Interventions: Device: Sham tDCS device; Device: Soterix tDCS device
Sponsors: The University of New South Wales; The University of New South Wales; Duke University; Emory University; Sheppard Pratt Health System; University of Medicine and Dentistry New Jersey; University of Texas
Not yet recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: AZD6765 iv; Drug: AZD6765 iv; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Condition: Acute Depressive Episode
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg; Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained-release 50 mg/day; Drug: desvenlafaxine succinate sustained-release 100 mg/day; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Device: Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
Sponsors: Cervel Neurotech, Inc.; Cervel Neurotech, Inc.
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: tasimelteon; Drug: placebo
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention:
Sponsors: Emory University; Emory University; National Institute of Mental Health (NIMH)
Recruiting - verified August 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Lurasidone 20 mg; Drug: Lurasidone 60 mg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Not yet recruiting - verified November 2011 - Condition: Major Depressive Disorder With Mixed Features
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Duloxetine; Drug: Escitalopram; Drug: BMS-820836 Placebo; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Condition: Treatment Outcome
Interventions: Drug: Lu AA21004; Drug: Escitalopram
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified July 2011 - Conditions: Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT; Drug: Placebo + ADT
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified July 2011 - Condition: Bipolar Disorder
Intervention: Drug: Lithium, valproate, lamotrigine
Sponsors: Emory University; Emory University
Recruiting - verified October 2011 - Conditions: Brain and Central Nervous System Tumors; Depression
Interventions: Drug: temozolomide; Drug: vorinostat; Other: survey administration; Procedure: magnetic resonance spectroscopic imaging
Sponsors: National Cancer Institute (NCI); Winship Cancer Institute of Emory University; National Cancer Institute (NCI)
Recruiting - verified April 2011 - Condition: Major Depressive Disorder
Interventions: Drug: PNB01 fixed dose combination of pipamperone and citalopram; Drug: Citalopram; Drug: Pipamperone
Sponsors: PharmaNeuroBoost N.V.; PharmaNeuroBoost N.V.
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Duloxetine; Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: Duloxetine; Drug: Placebo matching with Duloxetine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Bipolar
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Treatment Resistant Depression
Interventions: Drug: CX157; Drug: Placebo
Sponsors: CeNeRx BioPharma Inc.; CeNeRx BioPharma Inc.
Recruiting - verified October 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Escitalopram
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified February 2012 - Condition: Major Depressive Disorder (MDD)
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Intervention: Procedure: Whole-body Cooling
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Depression
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness TrialConditions: Posttraumatic Stress Disorder (PTSD); Depression
Interventions: Behavioral: STEPS UP; Behavioral: OUC
Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; Henry M. Jackson Foundation for the Advancement of Military Medicine; Department of Defense; RAND; RTI International
Recruiting - verified March 2012 - Conditions: Depression; Anxiety; Fatigue; Distress
Intervention:
Sponsors: Northside Hospital, Inc.; Northside Hospital, Inc.
Recruiting - verified March 2012 - Condition: Depression
Interventions: Drug: Armodafinil; Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Conditions: Bipolar; Depression
Intervention: Drug: lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified February 2012 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia; Procedure: Normothermic Control
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified September 2011 - Conditions: Bipolar Disorder; Bipolar Depression
Interventions: Drug: citalopram + mood stabilizer; Procedure: FDG PET scans; Procedure: MRI structural scans; Procedure: Genotyping; Procedure: Blood Draw; Drug: placebo + mood stabilizer
Sponsors: Tufts Medical Center; Tufts Medical Center; National Institute of Mental Health (NIMH)
Recruiting - verified July 2011 - Conditions: Depression; Panic Disorder; Generalized Anxiety Disorder; Post-Traumatic Stress Disorder; Obsessive Compulsive Disorder (OCD)
Intervention:
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH)
Recruiting - verified March 2009 - Condition: Major Depressive Disorder
Intervention: Device: Deep Brain Stimulator, implantable
Sponsors: Emory University; Emory University; The Dana Foundation
Recruiting - verified November 2011 - Condition: Depression
Interventions: Drug: Escitalopram; Drug: Duloxetine; Behavioral: Cognitive behavioral therapy (CBT)
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH); Emory University
Recruiting - verified December 2011
 |
Join Clinical Trials in Georgia for Depression |
